pharmachologic effect
The drug Betoptik is an antiglaucoma drug with a beta1-blocking effect (without internal sympathomimetic activity). Intraocular pressure decreases as a result of decreased production of aqueous humor.
The onset of the hypotensive effect occurs half an hour after instillation. The hypotensive effect reaches its maximum after 2 hours. The duration of action is 12 hours, that is, Betoptik needs to be instilled twice a day.
Compared to other beta blockers, this drug does not cause a decrease in blood supply to the fibers of the optic nerve, does not cause miosis, spasm of accommodation and the appearance of a veil before the eyes.
Betoptik S eye drops bottle 0.25% 5ml
A country
Belgium
Country of manufacture may vary depending on the batch of goods. Please check with the operator for detailed information when confirming your order.
Active substance
Betaxolol
Compound
benzalkonium chloride, mannitol, carbomer 974P, polystyrene sulfonic acid, boric acid, disodium edetate, N-lauroyl sarcosine, hydrochloric acid and/or sodium hydroxide solution (to maintain pH level), purified water.
pharmachologic effect
Antiglaucoma drug. Selective beta1-blocker without intrinsic sympathomimetic activity. It does not have a membrane-stabilizing (local anesthetic) effect. When applied topically, betaxolol reduces intraocular pressure due to a decrease in the production of intraocular fluid. The onset of the hypotensive effect is observed 30 minutes after instillation, the maximum effect develops after 2 hours. After a single instillation, the effect on ophthalmotonus persists for 12 h. Betaxolol (compared to other beta-blockers) does not cause a decrease in blood flow in the optic nerve. The use of Betoptik S does not lead to miosis, spasm of accommodation, hemeralopia, or a “veil” effect before the eyes (unlike miotics).
Indications for use
The drug is used to reduce intraocular pressure as monotherapy or in combination with other drugs for: - open-angle glaucoma; - ocular hypertension.
Mode of application
The drug is instilled into the conjunctival sac, 1-2 drops 2 times a day. In some patients, stabilization of intraocular pressure occurs within several weeks, so it is recommended to monitor intraocular pressure during the first month of treatment. If the clinical effectiveness of monotherapy is insufficient, combination therapy should be prescribed. Before use The bottle should be shaken. There is no sufficient experience with the use of the drug Betoptik S during pregnancy and lactation. The use of the drug during pregnancy and lactation (breastfeeding) is possible only if the expected benefit to the mother outweighs the potential risk to the fetus or child. There is no sufficient experience with the use of Betoptik S in children.
Interaction
With the simultaneous use of Betoptik C and beta-blockers for oral administration, the risk of side effects (both local and systemic) increases due to an additive effect (therefore, patients receiving this combination of drugs should be under medical supervision). When using Betoptik C in When combined with drugs that deplete catecholamines (such as reserpine), a decrease in blood pressure and bradycardia may occur.
Side effect
From the side of the organ of vision: often - short-term discomfort in the eyes after instillation; in some cases - blurred vision, pinpoint keratitis, decreased sensitivity of the cornea, sensation of a foreign body in the eye, lacrimation, photophobia, itching, dry eyes, redness of the eyes, anisocoria, inflammation, pain, decreased visual acuity. From the central nervous system: insomnia, depressive neuroses .
Contraindications
- sinus bradycardia; - AV block II and III degree; - cardiogenic shock; - severe heart failure; - hypersensitivity to the components of the drug. The drug should be prescribed with caution for diabetes mellitus, pheochromocytoma, Raynaud's syndrome.
Overdose
If excess amounts of the drug get into your eyes, rinse your eyes with warm water.
special instructions
The drug is prescribed with caution to patients with diabetes mellitus, since beta-blockers can mask the symptoms of acute hypoglycemia. The drug is prescribed with caution to patients with thyrotoxicosis, because beta blockers may mask symptoms of thyrotoxicosis (eg, tachycardia). In patients with suspected thyrotoxicosis, beta-blockers should not be abruptly discontinued, because this may cause an increase in symptoms. It should be borne in mind that beta-blockers can cause symptoms similar to those of myasthenia gravis (diplopia, ptosis, general weakness). Beta-blockers should be prescribed with caution to patients with severe dysfunction of the respiratory system. Despite the fact that clinical studies have shown no effect of betaxolol on respiratory function, the possibility of hypersensitivity to the drug cannot be excluded. Before elective surgery, beta-blockers should be gradually discontinued 48 hours before general anesthesia, because during general anesthesia, they may reduce the sensitivity of the myocardium to sympathetic stimulation. Patients treated with beta-blockers may have a history of atopy or anaphylactic reactions. If repeated hypersensitivity reactions develop, such patients may not be sensitive to the usual doses of epinephrine (adrenaline) required to relieve anaphylaxis. When instilled into the eyes, beta-blockers can be absorbed into the systemic circulation. In this case, the same side effects may occur as with systemic use. Cases of severe respiratory and cardiovascular disorders have been described, including fatal bronchospasm in patients with bronchial asthma and death from heart failure. Betoptik C has virtually no effect on blood pressure and heart rate. However, caution should be exercised when prescribing the drug to patients with AV block or heart failure. Treatment should be discontinued if symptoms of heart failure appear. Caution should be exercised when using betaxolol and adrenergic psychotropic drugs together. Betoptik S eye drops contain preservatives that can precipitate in soft contact lenses and have a damaging effect on eye tissue. Therefore, patients wearing contact lenses should remove them before using the drops and put them back no earlier than 20 minutes after instillation. When using the drug, avoid touching the pipette to any surface to avoid microbial contamination. Use in pediatrics Sufficient experience in using the drug Betoptik S children do not. Impact on the ability to drive vehicles and operate machinery If, after using the drops, the clarity of vision in patients is temporarily reduced, until it is restored, it is not recommended to drive a car or engage in activities that require increased attention and reaction.
Dispensing conditions in pharmacies
On prescription
special instructions
Patients with diabetes mellitus should be prescribed Betoptik with caution, as the symptoms of hypoglycemia become mild. With thyrotoxicosis, you also need to remember that the symptoms of the disease can be masked when using this medicine.
Before a planned operation, Betoptik should be gradually discontinued two days before anesthesia, because the sensitivity of the myocardium to sympathetic stimulation decreases.
Even when used topically, Betoptik can enter the systemic circulation and cause systemic reactions, including bronchospasm and disruption of the cardiovascular system.
The drug contains preservatives that are deposited on soft contact lenses, so they should be removed 20 minutes before instillation.
In some cases, after instillation of Betoptik, patients' vision temporarily decreases in clarity, so they should not drive until the condition normalizes.
Betoptic®
Diabetes:
β-blockers should be prescribed with caution to patients with a tendency to spontaneous hypoglycemia and patients with labile diabetes mellitus, since these drugs may mask the signs and symptoms of acute hypoglycemia.
Thyrotoxicosis:
β-blockers may mask some symptoms of hyperthyroidism (eg, tachycardia). In patients with suspected thyrotoxicosis, β-blockers should not be abruptly discontinued, as this may cause an increase in symptoms.
Myasthenia:
β-blockers may cause symptoms and signs similar to those of myasthenia gravis (eg, diplopia, ptosis, general weakness).
Surgery:
The anesthesiologist must be informed that the patient is taking betaxolol. Before a planned operation, beta-blockers should be gradually (not simultaneously!) withdrawn 48 hours before general anesthesia, because during general anesthesia, they may reduce the sensitivity of the myocardium to sympathetic stimulation necessary for cardiac function (for example, they may block the action of the systemic β-agonist epinephrine).
Pulmonology:
Caution should be exercised when prescribing β-blockers to patients with severely reduced respiratory system function. Despite the fact that clinical studies have shown no effect of betaxolol on respiratory function, the possibility of hypersensitivity to the drug should not be excluded.
Risk of developing an anaphylactic reaction:
Patients taking β-blockers may have a history of atopy or anaphylactic reactions. In case of repeated reactions, such patients may not be sensitive to the usual doses of epinephrine required to relieve anaphylaxis.
Betaxolol should be used with caution in patients with severe peripheral circulatory disorders (i.e., Raynaud's syndrome and pheochromocytoma).
When administered locally, β-blockers can enter the systemic circulation. Thus, beta-blockers can cause cardiovascular, pulmonary and other adverse reactions, as with intravenous and parenteral administration.
Cases of severe respiratory and cardiovascular disorders have been described, including death from bronchospasm in patients with bronchial asthma and death from heart failure.
Cerebrovascular disorders :
In patients with cardiovascular disease (eg, coronary artery disease, Prinzmetal's angina, heart failure) and hypotension, beta-blocker therapy should be critically evaluated and treatment with other active agents considered. Patients with cardiovascular disease should be closely monitored for signs of exacerbation of the disease and adverse reactions.
Corneal diseases
: β-blockers may cause dry eyes. The drug should be used with caution in patients with corneal diseases.
Choroidal detachment
: cases of detachment of the choroid have been described when using drugs that prevent the formation of intraocular fluid (for example, timolol, acetazolamide) after filtering operations.
Betoptik® S contains the preservative benzalkonium chloride, which can cause eye irritation and discoloration of soft contact lenses. Direct contact of the drug with soft contact lenses should be avoided. Patients using contact lenses should remove the lenses before using the drug and put them back no earlier than 15 minutes after instilling the drug.
Do not touch the tip of the dropper bottle to any surface to avoid contamination of the bottle and its contents. The bottle must be closed after each use.
